While the present study highlights the potential of NF-κB pathway activation and subsequent cytokine production to enhance tumor immunogenicity, it is crucial to acknowledge the context-dependent and often dual nature of NF-κB signaling in cancer. This evidence concerns the gene NFKB1 and neoplasm.